214390 — Kyongbo Pharmaceutical Co Income Statement
0.000.00%
HealthcareSpeculativeMicro Cap
Annual income statement for Kyongbo Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 191,706 | 215,285 | 170,660 | 196,265 | 216,357 |
Cost of Revenue | |||||
Gross Profit | 40,716 | 52,465 | 35,360 | 44,418 | 63,075 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 185,512 | 206,624 | 177,158 | 194,872 | 210,856 |
Operating Profit | 6,194 | 8,661 | -6,498 | 1,393 | 5,502 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6,982 | 14,031 | -9,933 | -615 | 2,172 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,285 | 9,404 | -7,495 | 611 | 2,974 |
Net Income Before Extraordinary Items | |||||
Net Income | 5,285 | 9,404 | -7,495 | 611 | 2,974 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,285 | 9,404 | -7,495 | 611 | 2,974 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 222 | 410 | -319 | 22.2 | 126 |
Dividends per Share |